Portal de Periódicos da CAPES

SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery

2018; Elsevier BV; Volume: 132; Issue: 17 Linguagem: Inglês

10.1182/blood-2018-03-840702

1528-0020

Élie Haddad, Brent R. Logan, Linda M. Griffith, Rebecca H. Buckley, Roberta Parrott, Susan E. Prockop, Trudy N. Small, Jessica Chaisson, Christopher C. Dvorak, Megan Murnane, Neena Kapoor, Hisham Abdel‐Azim, I. Celine Hanson, Caridad Martinez, Jack Bleesing, Sharat Chandra, Angela R. Smith, Matthew E. Cavanaugh, Soma Jyonouchi, Kathleen E. Sullivan, Lauri M. Burroughs, Suzanne Skoda‐Smith, Ann E. Haight, Audrey G. Tumlin, Troy C. Quigg, Candace Taylor, Blachy J. Dávila Saldaña, Michael D. Keller, Christine M. Seroogy, Kenneth DeSantes, Aleksandra Petrović, Jennifer W. Leiding, David C. Shyr, Hélène Decaluwe, Pierre Teira, Alfred P. Gillio, Alan P. Knutsen, Theodore B. Moore, Morris Kletzel, John Craddock, Victor Aquino, Jeffrey Davis, Lolie C. Yu, Geoff D.E. Cuvelier, Jeffrey J. Bednarski, Frederick D. Goldman, Elizabeth M. Kang, Evan Shereck, Matthew H. Porteus, James A. Connelly, Thomas A. Fleisher, Harry L. Malech, William T. Shearer, Paul Szabolcs, Monica S. Thakar, Mark T. Vander Lugt, Jennifer Heimall, Ziyan Yin, Michael A. Pulsipher, Sung‐Yun Pai, Donald B. Kohn, Jennifer M. Puck, Morton J. Cowan, Richard J. O’Reilly, Luigi D. Notarangelo,

Hematopoietic Stem Cell Transplantation

Key Points The genetic cause of SCID impacts on survival and immune reconstitution and should be considered in tailoring HCT for individual patients. Total and naive CD4+ cell counts in SCID patients 6 and 12 months post-HCT predict long-term survival and sustained immune reconstitution.